Axol Bioscience Ltd.. (10/13/20). "Press Release: Axol Bioscience Introduces Multi-electrode Array Screening Services for Human iPSC-derived Cells". Cambridge.

	Organisation	Axol Bioscience Ltd.
	Group	Axol Bioscience (Group)
	Organisation 2	Axion Biosystems Inc.
	Group	Axion Biosystems (Group)
	Product	cell research technology
	Product 2	Maestro Pro MEA system
	Person	Taylor, Liam (Axol Bioscience 202008– CEO before BBI Solutions)
	Person 2	Ricketts, Michelle A. (Codon Communications 202305– Founder before Zyme Communications + Axol Bioscience)

> Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery

> New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform

Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

As part of the new services, Axol is incorporating the Maestro Pro, a market-leading MEA platform from Axion Biosystems (Axion). This will allow customers to benefit from Axol’s extensive catalog of hiPSC-derived cells and in-house electrophysiology expertise, in combination with Axion’s most advanced offering. The Maestro Pro enables continuous label-free and real-time data acquisition and analysis from 768 electrodes, in up to a 96wp format, allowing for a high-throughput of data.

Axol’s MEA screening service offering will include:

> recording of field action potentials from neurons and cardiomyocytes

> local extracellular action potential (LEAP) and contractility recordings from cardiomyocytes

> cell visualization and multiplexing for microscopy and calcium imaging assays

> targeted panel compound and new chemical entity (NCE) screening

> cardiotoxicity and neurotoxicity testing

> cell, co-culture and disease model validation

> long-term cell proliferation studies

> bespoke projects and pilot studies.

The launch of Axol’s services follows the recent appointment of Liam Taylor as CEO at Axol, and forms part of the Company’s strategy to grow its iPSC technologies, products and services.

Liam Taylor, CEO, Axol Bioscience, said: “At Axol, we have worked extremely hard to establish ourselves as the market-leading provider of neuroscience and cardio-based hiPSC-derived cells. As we grow, it's now time to also offer our considerable in-house expertise to the preclinical drug discovery market. As such, we are proud to announce our new MEA capability utilizing the industry-leading Axion Maestro Pro platform.”

For further information about Axol’s MEA screening services, please visit: https://www.axolbio.com/page/mea-services

ENDS

Notes to Editors

Example images of neuronal and cardiac MEA recordings
Featured new MEA system and setup
For a high-resolution image please contact Zyme Communications

For further information please contact:

Axol Bioscience
John Burgess
Tel: +44 (0) 1223 751051
Email: j.burgess@axolbio.com

Zyme Communications
Dr. Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: michelle.ricketts@zymecommunications.com

About Axol Bioscience www.axolbio.com

Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.

The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.

Follow Axol Bioscience on Twitter @axolbio and LinkedIn @Axol Bioscience Ltd

Record changed: 2023-06-05